Introduction
ATTR Cardiomyopathy (ATTR-CM) is increasingly being recognized as a significant cause for heart failure in African American/Black adults (; ; ). Approximately 3.43% of African Americans harbor at least one copy of the. The TTR V122I allele, which is known to be associated with an increased risk of ATTR Cardiomyopathy (ATTR-CM), has a prevalence of approximately 3.43% in the African American population (). It has been estimated that Black Americans will lose nearly 1 million life years due to ATTR (). Genetic testing is currently recommended to patients with a suspected clinical diagnosis of ATTR-CM (). With the increasing development and potential availability of drugs targeting transthyretin (; ), debates on the possibilities of targeted presymptomatic genetic screening of vulnerable populations [including African American adults] for ATTR is emerging (; ) and topical considering the growing need to promote health equity ().
In this article, we report the arguments raised for and against genetic screening for ATTR in asymptomatic Black adults at a debate that was held at Arizona State University on 20 November 2023. The debate was attended by a board-certified Cardiologist, Genetic Counselors, and a Medical Geneticist, who are routinely involved in the clinical care of individuals with ATTR.
The debate: pros and cons
Points raised in support include: the increased risk of ATTR-CM in Black Americans, the high frequency of the pathogenic TTR variants [especially Val122Ile (or pV142I)], and the potential benefits of presymptomatic diagnosis in facilitating preventative and therapeutic options. The challenges highlighted include: the incomplete and age-dependent penetrance of TTR variants, uncertainties regarding acceptability of genetic screening, the risk of genetic discrimination, the uncertain impact for presymptomatic diagnosis, the costs of screening and limitations associated with variants of uncertain significance (VUS).
Pros: Team A argued that presymptomatic screening of African Americans, can pave the way for potentially preventative approaches, awareness of symptoms, and improved surveillance for ATTR (). Additionally, presymptomatic screening is likely to lead to timely initiation of treatment (). With the United States Food and Drug Administration’s (FDA) approval of Tafamidis (; ) and the growing possibilities () for other preventative as well as therapeutic approaches that may alter the disease course [such as RNA-targeted therapies [like Patisiran, Eplontersen, and Inotersen ()] CRISPR-Cas9 gene editing [e.g., nexiguran, and ziclumeran ()], team A argued that presymptomatic screening will result in early interventions including therapeutic and supportive management. Moreover, cascade testing of asymptomatic family members will be a potential secondary benefit of presymptomatic screening ().
Team A maintained that direct-to-consumer genetic tests are already reporting the common TTR variants (). Team A cited an example of a 45-year-old African American male who self-referred to genetics clinic in Arizona after a nonclinical, direct-to-consumer, genetic test revealed that he had a heterozygous TTR p. V122I variant, in the absence of personal or family history of symptoms related to ATTR. This case highlighted the potential for presymptomatic diagnosis in more African American patients, if opportunities for screening for common TTR variants are created.
Cons: Team B argued that the penetrance of ATTR appears to be incomplete as well as being subject to age-dependent penetrance (). In a study, involving 3,856 subjects from the Atherosclerosis Risk in Communities (ARIC) cohort, Selvaraj and colleagues reported significant increases in heart failure and mortality risk became apparent from around age 65 years in individuals harboring TTR p. V142I (). Approximately 150 variants in TTR have been identified in individuals with ATTR amyloidosis (). Team B maintained that a comprehensive screening program for Black adults may be difficult to achieve based on the current clinical scientific knowledge of TTR variants due to challenges associated with variants of uncertain significance [VUS] (; ). The psychological, ethical, and economic consequences of VUS cannot be overemphasized (; ; ; ; ). Team B explained that presymptomatic screening for ATTR may need to focus on established pathogenic and likely pathogenic TTR variants, potentially limiting the capacity of such screening program for individuals with non-founder mutations.
Team B contended that the uptake of ethnicity centered presymptomatic genetic screening might be low in Black communities for historic reasons () without appropriate pre-test counseling and a well-defined post-test counseling and clinical management pathway (). Team B cited that the current limitations of Genetic Information Nondiscrimination Act (GINA) may also complicate presymptomatic pre-test counselling for an already vulnerable population (). The potential costs associated with widespread presymptomatic genetic screening for Black adults were also underscored by team B. The cost effectiveness of genomic population health screening programs is a subject of ongoing investigations that is topical considering the resource constrains faced by many healthcare systems. A recent review of eight modeling studies of cost effectiveness of genomic population screening in adults for three countries [United States, United Kingdom and Australia] using quality-adjusted life year (QALYs) and incremental cost-effectiveness ratio (ICER) as well as willingness to pay (WTP) threshold suggests that genomic population health screening is likely to be cost-effective ().
Discussion and conclusion
This debate highlights the complexities that are potentially associated with implementing routine genetic screening for ATTR in the Black population despite the growing need for the public health screening program. The panel recognized that the increased risk of ATTR cardiac amyloidosis in African American adults (; ; ) together with the challenges of racial disparities in access to care results in increased vulnerability (). Screening approaches will need to be guided by allele frequency, penetrance, predictive value, and preventative as well as therapeutic implications.
The development of programs that can create an improved public awareness of the increased vulnerability of African Americans to ATTR-CM is increasingly becoming necessary. The results of this debate and new evidence suggest that early detection of ATTR-CM via widespread ATTR variant genetic testing in asymptomatic Black adults may potentially improve patient outcomes (; ; ; ), however to facilitate increased uptake of genetic testing, we believe that additional evidence generation on the risks and benefits of genetic screening of at-risk communities is required (). A recent study estimated that Black Americans will lose nearly 1 million life years due to ATTR (). The ongoing and future clinical trials may shed further light on novel approaches to delay the development of ATTR CM and/or polyneuropathy in asymptomatic patients ().
The panel concluded that clinical genetic tests for the common TTR variants should be increasingly offered to Black adults, following appropriate risk and culturally tailored pretest counseling, considering the preventative and therapeutic benefits. The panel posits that approaches to increase the awareness of ATTR-CM in Black people will be beneficial. Pilot programs, and cost-effectiveness clinical trials, as well as culturally tailored pre and post-test counseling are therefore warranted.
Statements
Author contributions
IB: Writing – review and editing, Writing – original draft. SiS: Writing – original draft, Writing – review and editing. JM: Writing – original draft, Writing – review and editing. HG: Writing – review and editing, Writing – original draft. SoS: Writing – review and editing, Writing – original draft. AB: Writing – review and editing, Writing – original draft. MS: Writing – original draft, Writing – review and editing. KB: Writing – review and editing, Writing – original draft. PU: Writing – original draft, Writing – review and editing. SD: Conceptualization, Writing – review and editing, Funding acquisition, Writing – original draft. MO: Project administration, Writing – original draft, Writing – review and editing, Conceptualization, Supervision.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. The debate was funded by Arizona Biomedical Research Consortium. This study also received support from Mayo Clinic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AimoA.CastiglioneV.RapezziC.FranziniM.PanichellaG.VergaroG.et al (2022). RNA-Targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol.19 (10), 655–667. 10.1038/s41569-022-00683-z
2
BrandonD. T.IsaacL. A.LaVeistT. A. (2005). The legacy of tuskegee and trust in medical care: is tuskegee responsible for race differences in mistrust of medical care?J. Natl. Med. Assoc.97 (7), 951–956.
3
BurkeW.ParensE.ChungW. K.BergerS. M.AppelbaumP. S. (2022). The challenge of genetic variants of uncertain clinical significance: a narrative review. Ann. Intern Med.175 (7), 994–1000. 10.7326/M21-4109
4
Campinha-BacoteJ. (2024). Promoting health equity among marginalized and vulnerable populations. Nurs. Clin. North Am.59 (1), 109–120. 10.1016/j.cnur.2023.11.009
5
CostabelJ. P.SuarezL. L.RochlaniY.MasriA.SlipczukL.BerriosE. (2025). Transthyretin amyloid cardiomyopathy: evolving therapies, expanding hope. Prog. Cardiovasc Dis. 10.1016/j.pcad.2025.07.011
6
FavalliV.TiniG.BonettiE.VozzaG.GuidaA.GandiniS.et al (2021). Machine learning-based reclassification of germline variants of unknown significance: the RENOVO algorithm. Am. J. Hum. Genet.108 (4), 682–695. 10.1016/j.ajhg.2021.03.010
7
FedericiG.SodduS. (2020). Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. J. Exp. Clin. Cancer Res.39 (1), 46. 10.1186/s13046-020-01554-6
8
FontanaM.SolomonS. D.KachadourianJ.WalshL.RochaR.LebwohlD.et al (2024). CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. N. Engl. J. Med.391 (23), 2231–2241. 10.1056/NEJMoa2412309
9
Garcia-PaviaP. G. J.AdamsD.SomanP.GillmoreJ. D.ConceicaoI.CoelhoT.et al (2024). Rationale and design of ACT-EARLY, the acordamidis transthyretin amyloidosis prevention trial. Amyloid J. Protein Fold. Disord.31, S70.
10
HussainB.DuhanS.PatelB.ChangY. C.HamzaM.NajamM.et al (2025). Tafamidis: a game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy. Curr. Probl. Cardiol.50 (9), 103129. 10.1016/j.cpcardiol.2025.103129
11
JacobsonD. R.AlexanderA. A.TagoeC.BuxbaumJ. N. (2015). Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 african-americans. Amyloid22 (3), 171–174. 10.3109/13506129.2015.1051219
12
JeanneM.ChungW. K. (2025). Prenatal genomic sequencing: navigating uncertainty. Semin. Perinatol.49 (3), 152058. 10.1016/j.semperi.2025.152058
13
MakhnoonS.ShirtsB. H.BowenD. J. (2019a). Patients' perspectives of variants of uncertain significance and strategies for uncertainty management. J. Genet. Couns.28 (2), 313–325. 10.1002/jgc4.1075
14
MakhnoonS.GarrettL. T.BurkeW.BowenD. J.ShirtsB. H. (2019b). Experiences of patients seeking to participate in variant of uncertain significance reclassification research. J. Community Genet.10 (2), 189–196. 10.1007/s12687-018-0375-3
15
MaurerM. S.HannaM.GroganM.DispenzieriA.WittelesR.DrachmanB.et al (2016). Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey). J. Am. Coll. Cardiol.68 (2), 161–172. 10.1016/j.jacc.2016.03.596
16
MaurerM. S.SchwartzJ. H.GundapaneniB.ElliottP. M.MerliniG.Waddington-CruzM.et al (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med.379 (11), 1007–1016. 10.1056/NEJMoa1805689
17
MaurerM. S.BokhariS.DamyT.DorbalaS.DrachmanB. M.FontanaM.et al (2019). Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ. Heart Fail12 (9), e006075. 10.1161/CIRCHEARTFAILURE.119.006075
18
MightonC.ClausenM.ShickhS.BaxterN. N.ScheerA.SebastianA.et al (2023). How do members of the public expect to use variants of uncertain significance in their health care? A population-based survey. Genet. Med.25 (5), 100819. 10.1016/j.gim.2023.100819
19
MondaE.CirilloC.VerrilloF.PalmieroG.FalcoL.AimoA.et al (2024). Genotype-phenotype correlations in ATTR amyloidosis: a clinical update. Heart Fail Clin.20 (3), 317–323. 10.1016/j.hfc.2024.03.006
20
MullerS. A.van der MeerM. G.OerlemansM. (2023). Racial and genetic differences: possible health disparities in transthyretin amyloid cardiomyopathy patients?JACC Heart Fail11 (1), 130. 10.1016/j.jchf.2022.11.009
21
ObiciL.KuksJ. B.BuadesJ.AdamsD.SuhrO. B.CoelhoT.et al (2016). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr. Opin. Neurol.29 (Suppl. 1), S27–S35. 10.1097/WCO.0000000000000290
22
PrinceA. E. R.SuterS. M.UhlmannW. R.SchererA. M. (2022). The goldilocks conundrum: disclosing discrimination risks in informed consent. J. Genet. Couns.31 (6), 1383–1393. 10.1002/jgc4.1613
23
RapezziC.ElliottP.DamyT.Nativi-NicolauJ.BerkJ. L.VelazquezE. J.et al (2021). Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail9 (2), 115–123. 10.1016/j.jchf.2020.09.011
24
SelvarajS.ClaggettB. L.QuartaC. C.YuB.InciardiR. M.BuxbaumJ. N.et al (2023). Age dependency of cardiovascular outcomes with the amyloidogenic pV142I transthyretin variant among black individuals in the US. JAMA Cardiol.8 (8), 784–788. 10.1001/jamacardio.2023.1525
25
SelvarajS.ClaggettB.ShahS. H.MentzR. J.KhouriM. G.ManichaikulA. W.et al (2024). Cardiovascular burden of the V142I transthyretin variant. JAMA331 (21), 1824–1833. 10.1001/jama.2024.4467
26
ShahK. B.MankadA. K.CastanoA.AkinboboyeO. O.DuncanP. B.FergusI. V.et al (2016). Transthyretin cardiac amyloidosis in black Americans. Circ. Heart Fail9 (6), e002558. 10.1161/CIRCHEARTFAILURE.115.002558
27
SkirtonH.GoldsmithL.JacksonL.TibbenA. (2013). Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions. Eur. J. Hum. Genet.21 (3), 256–260. 10.1038/ejhg.2012.174
28
SoperE. R.SuckielS. A.BraganzaG. T.KontorovichA. R.KennyE. E.Abul-HusnN. S. (2021). Genomic screening identifies individuals at high risk for hereditary transthyretin amyloidosis. J. Pers. Med.11 (1), 49. 10.3390/jpm11010049
29
Spencer-BonillaG.NjorogeJ. N.PearsonK.WittelesR. M.ArasM. A.AlexanderK. M. (2021). Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr. Cardiovasc Risk Rep.15 (6), 8. 10.1007/s12170-021-00670-y
30
UedaM.SekijimaY.KoikeH.YamashitaT.YoshinagaT.IshiiT.et al (2020). Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J. Neurol. Sci.414, 116813. 10.1016/j.jns.2020.116813
31
WildinR. S. (2024). Cost effectiveness of genomic population health screening in adults: a review of modeling studies and future directions. J. Appl. Lab. Med.9 (1), 92–103. 10.1093/jalm/jfad093
32
WittelesR. M.BokhariS.DamyT.ElliottP. M.FalkR. H.FineN. M.et al (2019). Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail7 (8), 709–716. 10.1016/j.jchf.2019.04.010
Summary
Keywords
Black, transthyretin, amyloidosis, genetic, screening
Citation
Bharaj I, Singh SJ, Munaim J, Grewal H, Sabrowsky S, Boshara A, Silver MA, Brendish KH, Underwood P, Dev S and Osundiji MA (2025) The potential clinical and public health implications of presymptomatic genetic testing for transthyretin amyloidosis in African American/Black adults in the United States. Front. Genet. 16:1658636. doi: 10.3389/fgene.2025.1658636
Received
02 July 2025
Accepted
01 September 2025
Published
15 September 2025
Volume
16 - 2025
Edited by
Jared C. Roach, Institute for Systems Biology (ISB), United States
Updates
Copyright
© 2025 Bharaj, Singh, Munaim, Grewal, Sabrowsky, Boshara, Silver, Brendish, Underwood, Dev and Osundiji.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mayowa A. Osundiji, osundiji.mayowa@mayo.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.